


AMENDMENTS TO THE CLAIMS

1) (Currently amended) Amino acid diamides in non- α position of formula (1)



(1)


wherein:

$n = 2$ to 8 ;

R_1 is selected from amongst the group consisting of functional groups alkyl, halogen, NO_2 , OH , OCH_3 either alone or associated and a combination thereof; and

R_2 is selected from the group consisting of functional groups H, alkyl, halogen, NO_2 , OH , and OCH_3 , which are useful as adjuvants for the administration of biological active agents.


2) (Currently amended) Compounds Diamides according to claim 1, wherein they present the following structure comprising:



(2)

wherein $n = 2$ to 8 .


3) (Currently amended) ~~Compounds Diamides according to claim 1, wherein they present the following structure comprising:~~



(3)

wherein n= 2 to 8.

4) (Currently amended) Compounds according to claim 1, wherein they present the following structure:

n= 2 to 8

(4).

5) (Currently amended) Pharmaceutical compositions according to claim 1, wherein they comprise heparin oligosaccharides and at least one compound from formula (1) A pharmaceutical composition comprising heparin oligosaccharides and at least one compound according to claim 1.


6) (Currently amended) Pharmaceutical compositions according to claim 5, wherein they comprise compounds according to formula (2) and glycosaminoglycan oligosaccharides A pharmaceutical composition comprising at least one compound according to claim 2 and glycosaminoglycan oligosaccharides.

7) (Currently amended) Pharmaceutical compositions according to claim 5, wherein they comprise compounds according to formula (3) and glycosaminoglycan oligosaccharides A

pharmaceutical composition comprising at least one compound according to claim 3 and glycosaminoglycan oligosaccharides.


8) (Currently amended) ~~Pharmaceutical compositions according to claim 5, wherein they comprise compounds according to formula (4) and glycosaminoglycan oligosaccharides~~ A pharmaceutical composition comprising at least one compound according to claim 4 and glycosaminoglycan oligosaccharides.

9) (Currently amended) A pharmaceutical composition ~~Pharmaceutical compositions according to claim 5, wherein they comprise at least one compound of structure comprising~~




and Bemiparin.

10) (Currently amended) A pharmaceutical composition ~~Pharmaceutical compositions according to claim 5, wherein they comprise at least one compound of structure comprising~~



and Bemiparin.

11) (Currently amended) A pharmaceutical composition Pharmaceutical compositions according to claim 5, wherein they comprise at least one compound of structure comprising



and Bemiparin.

12) (Currently amended) A pharmaceutical composition Pharmaceutical compositions according to claim 1, wherein they comprise compounds at least one compound according to formula (1) and at least one active agent selected from the group composed consisting of heparin, dermatan sulphate, chondroitin sulphate, heparan sulphate and oligosaccharide derivatives.

13) Canceled.

14) Canceled.

15) (New) A method of enhancing the colonic absorption of a glycosaminoglycan or glycosaminoglycan oligosaccharide following administration thereof, the method comprising: orally or intracolonically administering to a subject in need thereof a compound according to any one of claims 1 – 4 or 5 and a glycosaminoglycan or glycosaminoglycan oligosaccharide thereby enhancing the colonic absorption of the glycosaminoglycan or glycosaminoglycan oligosaccharide.

16) (New) A method of treating thrombosis, inflammation, cancer or allergy comprising: administering to a subject in need thereof a compound according to any one of claims 1 – 4 or 5 and a glycosaminoglycan or glycosaminoglycan oligosaccharide.

17) (New) The method of claim 16, wherein the step of administering is selected from the group consisting of oral, intraduodenal, intracolonic and pulmonary administration.